38 results about "LGR5" patented technology

The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.

The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.

An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.

The invention belongs to the field of biological inner ear research, and particularly discloses a biological factor and application thereof in promoting regeneration of inner ear hair cells. The biological factor is a histone deubiquitination enzyme USP16 in a single dose state, has the activity of promoting proliferation and differentiation of inner ear stem cells into hair cells, and has an amino acid sequence as shown in SEQ NO.1. The inventor finds the space-time expression mode of USP16 in the inner ear of a mouse for the first time, subsequently finds that after the gene is knocked downin mouse hair cells, hair cell apoptosis is caused such that the normal auditory function is influenced, and finally finds that after the USP16 gene is knocked down from the inner ear Lgr5 positive inner ear stem cells, proliferation of the inner ear stem cells is promoted such that hair cells proliferate. The USP16 gene disclosed by the invention lays an important foundation for subsequent research on mouse hair cell regeneration.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention relates to the technical field of biology, in particular to a method for regulating and controlling proliferation and differentiation of inner ear stem cells by Rps14 and Foxg1 and application of the method. The method comprises the following steps: firstly, regulating and controlling proliferation and differentiation of Lgr5+ inner ear stem cells by an Rps14 gene: 1, culturing OC-1 cells; 2, knocking out the Rps14 gene from the siRNA; 3, carrying out isolated culture of Lgr5+ progenitor cells and Rps14 gene knockout; and 4, carrying out the biological effect of the Rps14 gene knockout Lgr5+ progenitor cells; and secondly, detecting the influence of knockout of the Foxg1 in the Lgr5+ progenitor cells on hair cell proliferation. According to the method, an Lgr5-EGFP-CreERT2 mouse and a Foxg1-floxp mouse are hybridized, and the Foxg1 is conditionally knocked out from the Lgr5+ progenitor cells, so that the fact that the cochlea of a newborn mouse can be induced to generate extra IPCs by knocking out the Foxg1 from the Lgr5+ progenitor cells is found. Rps14 genes are knocked out through OC-1 cells by utilizing different siRNAs, and the transfection effect is detected through RT-qPCR; and after the Lgr5+ inner ear stem cells are subjected to isolated culture and transfection, proliferation and differentiation are detected, and a balling differentiation experiment on the Lgr5+ stem cells shows that knock-down of the Rps14 gene can inhibit proliferation of the stem cells and has no influence on differentiation.

The invention discloses a method for combined induction of increase in endogenous Lgr5+ liver stem cells and an application of the method, and in particular a method for inducing the endogenous Lgr5+liver stem cells through combination of soluble protein molecules HGF and Rspo1. The soluble ligand can reach tissue stem cells through intravenous injection, and the soluble ligand, combined with a receptor, can activate the tissue stem cells. According to the method, the Lgr5+ liver stem cells are taken as targets. According to the method provided by the invention, on the basis of self-renewal and multifunctional differentiation capacities of various tissue and organ endogenous stem cells, the tissue and organ endogenous stem cells in a body are directly stimulated via the soluble molecules,so that self-renewal / regeneration of tissues and organs can be promoted; and from the aspects of application convenience, cost saving and safety, feasibility is enhanced.

The invention relates to application of Rivastigmine in preparation of antiradiation drugs and belongs to the technical field of medicines. According to the application of the Rivastigmine in the preparation of the antiradiation drugs, provided by the invention, researches discover that the Rivastigmine can be used for remarkably promoting propagation of Lgr5<+> stem cells subjected to 10Gy irradiation (after 10 days of the 10Gy irradiation, the propagation amount of the Lgr5<+> stem cells cultured in a Rivastigmine-containing culture solution is 14.2 times that of the Lgr5<+> stem cells cultured in a Rivastigmine-free culture solution), the death rate of mice subjected to the 10Gy irradiation can be lowered remarkably (mice free of intraperitoneal injection of the Rivastigmine fully die in 10 days after whole-body irradiation of 10Gy, and the survival rate of mice with intraperitoneal injection of the Rivastigmine is still higher than 40% in 30 days after whole-body irradiation of 10Gy), and the Rivastigmine has a good antiradiation action.

The invention relates to the field of inner ear stem cells, in particular to a method for regulating proliferation and differentiation of inner ear stem cells through Rassf2 and application of Rassf2 in hair cell regeneration. The regulation and control method comprises the following steps: 1, detecting expression conditions of Shh or Hippo and Rassf2 in cochlea in a wild type mouse; 2, studying the effect of Shh or Hippo and Rassf2 on proliferation and differentiation of the inner ear stem cells which are separated in a flow mode in an in-vitro experiment; 3, researching the effects of Shh or Hippo and Rassf2 on a living hair cell neomycin injury model. By using the Lgr5-EGFP-CreERT2 tool mouse, the separation of the inner ear stem cells (Lgr5 positive cells) is accurate and a large amount of the inner ear stem cells (Lgr5 positive cells) can be realized, and a relatively good research premise can be achieved: the Lgr5 positive inner ear stem cells of the mouse are sorted. Besides, after the separated inner ear stem cells are subjected to balling and differentiation experiments by researching Shh, Hippo and Rassf2 in an in-vitro experiment, the specific action mechanism of Shh, Hippo and Rassf2 in regulation and control of proliferation and differentiation of the inner ear stem cells and hair cell regeneration can be deeply explored.

The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and / or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49 / LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and / or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49 / LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and / or promoting proliferation of an eye cell, comprising R-spondins.